Life Science Insights

Investors fund programs with a clear path to launch.

Understand why manufacturing and safety strategy matter early—and how CMC and tox shape investor confidence and program value.

This episode demystifies CMC and toxicology—and explains why they matter far earlier than most founders expect. Dr. Silvon shows how manufacturing and safety planning shape investor confidence, regulatory credibility, and program value. You’ll learn what questions investors are asking even when they don’t say so, and how early technical rigor can de-risk your program. If you’ve ever felt unprepared discussing development strategy, scalability, or safety planning, this conversation gives you the understanding and language needed to engage confidently and position your company for funding and long-term success.

Regulation doesn’t have to be a black box.

Learn how and when to engage FDA, what regulators expect early, and how smart interaction reduces risk and wasted effort.

This episode helps founders understand how to engage FDA early and productively. Dr. Glass explains when to initiate regulatory conversations, what agencies are really looking for, and how early feedback can shape smarter development strategies. You’ll learn how to avoid common regulatory missteps and how to view FDA as a partner in risk reduction rather than an obstacle. For academic and first-time founders who find regulation intimidating or opaque, this conversation brings clarity, structure, and confidence to one of the most critical (and misunderstood) parts of building a life-science company.